77 Evaluation of clarity of the STOPP/START criteria 18. Connor MNO, Gallagher P, Mahony DO, Byrne S, Sullivan DO, Ryan C. Corrigendum. Age Ageing. 2017;47(3):489–489. 19. AGREE II Instrument. 2017. Appraisal of Guidelines for Research and Evaluation consortium (online). Available at: https://www.agreetrust.org/wp-content/ uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017. pdf. Accessed March 26, 2019. 20. Brouwers MC, Makarski J, Kastner M et al. The Guideline Implementability Decision Excellence Model (GUIDE-M): A mixed methods approach to create an international resource to advance the practice guideline field. Implement Sci. 2015;10(1):1–11. 21. Scheuermann RH, Ceusters W, Smith B. Toward an ontological treatment of disease and diagnosis. Translat Bioinforma. 2009;2009(i):116–20. 22. Eudralex. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Union. 2001:L311:67. Consolidated version: 16/11/2012. Available from: https://ec.europa.eu/health/documents/eudralex/vol-1_nl#dir. Last accessed: 06/11/2019. 23. Curtin D, Gallagher PF, O’Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019; 10. 24. Nederlof M, Stoker LJ, Egberts TCG, Heerdink ER. Instructions for clinical and biomarker monitoring in the Summary of Product Characteristics (SmPC) for psychotropic drugs: Overview and applicability in clinical practice. J Psychopharmacol. 2015;29(12):1248–54. 25. De Koning FHP, Egberts TCG, De Smet PAGM, Van SolingeWW, Geerts AFJ. Instructions on laboratory monitoring in 200 drug labels. Clin Chem Lab Med. 2012;50(8):1351–8. 26. Farell B, Pottie K, Rojas-Fernandez CH et al. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS One. 2016; 11(8). 27. Reeve E, Thompson W, Farrell B. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017 Mar;38:3-11. 28. Bruyère Research Institute. Benzodiazepine & Z-Drug (BZRA) Deprescribing Algorithm. 2019. Available from: https://deprescribing.org/resources/deprescribing-guidelinesalgorithms/. Last accessed: 13/11/2019. 29. Siering U, Eikermann M, Hausner E, Hoffmann-Eßer W, Neugebauer EA. Appraisal tools for clinical practice guidelines: A systematic review. PLoS One. 2013;8(12): e82915. 30. Guyatt GH, Oxman AD, Kunz R et al. GRADE: Going from Evidence to Recommendations. BMJ. 2008;336(7652):1049-51. 31. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: A systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. 32. Huibers CJA, Sallevelt BTGM, De Groot D et al. Conversion of STOPP/START version 2 into coded algorithms for software implementation: a multidisciplinary consensus procedure. Int J Med Inform. 2019;125:110–7. 33. Anrys P, Boland B, Degryse JM et al. STOPP/START version 2-development of software applications: Easier said than done? Age Ageing. 2016;45(5):590–3. 2
RkJQdWJsaXNoZXIy MTk4NDMw